Welcome to the IPE Reference Hub. This site uses cookies. Read our policy.

AXA Investment Managers

2023 Top 500 ranking: 25

How genetics innovation has expanded biotech investment opportunities

AXA IM - genetics innovation

From cancer and heart disease to rarer but equally devastating diseases, the development of life-saving treatments has been turbo-charged in recent years by our improved understanding of one key area of medicine – genetics.

This is premium content

You are not logged in, Sign in or register to request access. 
Please note: If you had prior access to this content you may need to sign in again.

Asset Owners

If you are an institutional investor you are eligable for free access to all premium content.


Asset Managers

Asset managers with enhanced profiles are eligable for full access.

Please sign-in using your work email address or: